AffyImmune Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- AffyImmune Therapeutics's estimated annual revenue is currently $3.1M per year.
- AffyImmune Therapeutics's estimated revenue per employee is $77,500
- AffyImmune Therapeutics's total funding is $28.9M.
Employee Data
- AffyImmune Therapeutics has 40 Employees.
- AffyImmune Therapeutics grew their employee count by 38% last year.
AffyImmune Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | President and CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | SVP and Head Clinical Development | Reveal Email/Phone |
5 | SVP CMC | Reveal Email/Phone |
6 | Head Quality | Reveal Email/Phone |
7 | VP Clinical Operations | Reveal Email/Phone |
8 | Executive Director, Clinical Science | Reveal Email/Phone |
9 | Jr. Clinical Trial Manager | Reveal Email/Phone |
10 | Quality Assurance Manager | Reveal Email/Phone |
AffyImmune Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is AffyImmune Therapeutics?
Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.
keywords:N/A
$28.9M
Total Funding
40
Number of Employees
$3.1M
Revenue (est)
38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AffyImmune Therapeutics News
NATICK, Mass., April 6, 2022 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track...
Other Companies in Natick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.9M | 41 | -5% | N/A |
#2 | $8.4M | 42 | -5% | N/A |
#3 | N/A | 42 | 2% | N/A |
#4 | $7.6M | 43 | 19% | N/A |
#5 | $5.1M | 44 | 2% | N/A |